What Кетамин treats: Main Uses and Benefits

Anesthetic Support for Critical Procedures

The medication is commonly used as a general anesthetic and is considered relevant for brief medical procedures that do not require deep muscle relaxation. This supports the management of conditions presenting with acute or disruptive symptom patterns, such as those requiring immediate surgical or emergency intervention (e.g., fracture reduction). This application is relevant in clinical settings that involve acute or unstable symptom patterns, helping to provide supportive symptom management during difficult episodes by easing distress and contributing to a more manageable experience and patient comfort during necessary interventions.

Relief for Severe Acute and Chronic Pain

Ketamine is commonly used to help manage symptom clusters that may become intense or disruptive, such as severe acute pain from trauma or in the postoperative setting. It is applied in scenarios where additional management of discomfort is required for certain chronic pain syndromes that are difficult to manage with conventional relief methods. This provides support that helps ease the overall symptom burden, contributing to improved comfort during periods of heightened symptoms, and helps to support pain management goals by assisting with the overall symptom load.

Stabilization in Treatment-Resistant Mood Conditions

The medication is considered relevant for easing symptoms associated with treatment-resistant depression and acute suicidal ideation—conditions where symptoms have failed to respond adequately to multiple prior therapies. Used in specialized contexts, it offers symptomatic relief that helps patients cope more steadily with difficult episodes, applied when symptoms create noticeable functional strain and require supportive symptomatic management to assist with maintaining functional stability.

---

Quick Fact: Relief for Severe Pain and Depressive Crisis The medication is considered relevant for easing symptoms related to severe physical discomfort and treatment-resistant mood conditions.

Regulatory References

1. NIH National Library of Medicine

Official Eligibility and Non-Eligibility Status

Ketamine is an approved anesthetic agent for use in adults and children. However, official regulatory documents define strict criteria for eligibility based on patient health status and demographics.

Absolute Contraindications

Use of the medication is strictly prohibited in patients with known hypersensitivity to the drug. It is also contraindicated in individuals for whom a significant elevation of blood pressure would constitute a serious hazard, including those with severe coronary or myocardial disease or conditions like pre-eclampsia.

Conditional Use and Restrictions

Certain groups require special consideration or caution:

• Neurological/Psychiatric: Caution is mandatory for patients with pre-existing psychiatric illness (e.g., schizophrenia) or conditions that increase intracranial pressure.
• Age Groups: Safety is not established for anesthetic use in children younger than 16 years. Prolonged use in children under three years carries a neurotoxicity warning. Dose selection for older adults requires caution.
• Organ Function: Dose reductions should be considered in patients with liver impairment (cirrhosis).
• Reproductive Status: Use is generally not recommended during pregnancy or lactation as safety has not been established, although it may be conditionally permitted for use during delivery.

Interactions with other medicines and products

Ketamine's officially documented interaction profile is governed by both pharmacokinetic and pharmacodynamic mechanisms, according to regulatory sources.

Pharmacokinetic (Metabolic) Interactions

Co-administration with CYP3A4 inhibitors—such as fluconazole or ketoconazole—can lead to a pharmacokinetic interaction that increases Ketamine exposure (elevated plasma concentrations) by reducing its clearance. Conversely, substances that induce CYP3A4, such as the herbal product St. John's Wort, may decrease Ketamine exposure. The drug is primarily metabolized in the liver, meaning the duration and severity of metabolic interactions may be altered in the presence of hepatic impairment.

Pharmacodynamic Interactions and Restrictions

Co-administration with other Central Nervous System (CNS) depressants (e.g., benzodiazepines, narcotic analgesics, and alcohol) may result in additive pharmacodynamic effects, specifically leading to profound sedation and the potential for respiratory depression. The combination with sympathomimetics (e.g., thyroid hormones, vasopressin) may potentiate Ketamine’s cardiovascular effects, resulting in elevated blood pressure and heart rate.

Mandatory procedural constraints exist for certain combinations: Ketamine is chemically incompatible with barbiturates and diazepam and must not be mixed with them in the same syringe or infusion solution due to the risk of precipitate formation.

Ketamine is a lipophilic substituted cyclohexanone. Its primary molecular mechanism involves acting as a non-competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor, a major ionotropic glutamate receptor. This antagonism occurs through binding within the ion channel pore, restricting the flow of cations.

Blocking the NMDA receptor inhibits downstream glutamatergic neurotransmission, which consequently reduces excitatory postsynaptic potentials (EPSPs). The agent also interacts with mu-opioid receptors and voltage-gated mathrmNa^+ channels. Furthermore, its interaction with alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors modulates synaptic plasticity by enhancing AMPA receptor function in specific pathways. Collectively, these actions modulate neurotransmission across multiple brain regions, resulting in central nervous system depression.

Instruction Map: How to use Ketamine — Official Administration Guidelines

Parameter	Official Instruction
Route of Administration	The sterile solution for injection is administered Intravenously (IV) or Intramuscularly (IM). The Esketamine nasal spray is administered Intranasally.
Dosing Schedule	Anesthesia (IV): Initial induction dose is typically 1 mg/kg to 4.5 mg/kg. Anesthesia (IM): Initial induction dose is 6.5 mg/kg to 13 mg/kg. Depression (Nasal): Dosing is 56 mg or 84 mg based on the phase and patient response.
Timing in relation to meals	For the nasal spray, patients must avoid food for at least 2 hours and avoid drinking liquids at least 30 minutes prior to administration.
Preparation Requirements	The 100 mg/mL injection solution must be diluted prior to IV injection, often using 0.9% Sodium Chloride or 5% Dextrose in Water to a final concentration of 1 mg/mL or 2 mg/mL for continuous infusion.
Age-Group Administration Rules	Older Adults: Dose selection should be cautious, typically starting at the low end of the dosing range. Pediatric: IM induction dosing is weight-based, ranging from 6.5 mg/kg to 13 mg/kg.
Missed-Dose Rules	If a scheduled nasal spray dose is missed, treatment should be resumed with the next dose as soon as possible, continuing with the existing schedule.
Special Procedural Conditions	The IV induction dose must be administered slowly over 60 seconds. The Esketamine nasal spray requires direct supervision by a healthcare provider in a certified setting and a mandatory 2-hour observation period post-administration.

---

Instruction Classifications (high-level)

Parameter	Classification
Administration method type	Parenteral (IV/IM) and Intranasal.
Frequency pattern	As-needed/Intermittent for anesthetic use; Twice-weekly changing to weekly/bi-weekly for chronic nasal use.
Basis of Instructions	Official prescribing information.
Use-context constraints	Requires dilution for high-concentration IV use; requires supervised, monitored setting for intranasal use; incompatible with barbiturates in the same syringe.

---

Resulting Procedural Structure

Official step sequence for Nasal Spray (Treatment-Resistant Depression):

• The patient is advised to avoid food for 2 hours and liquids for 30 minutes before the session.
• The patient self-administers the prescribed dose (56 mg or 84 mg) only under the direct supervision of a healthcare provider in a certified setting.
• The healthcare provider must monitor the patient for at least two hours following administration.

Connection to the overall use protocol

Official instructions mandate that the method of administration (parenteral versus intranasal) must align strictly with the usage context, requiring either a rapid IV/IM procedure or a highly controlled, monitored course of scheduled doses. These rules establish a standardized protocol for drug delivery, defining specific dilution requirements, fixed dosing ranges, and mandatory supervision and post-administration observation periods across all approved methods.

Research evidence / Overview of Studies for Ketamine

Evidence for Use in General Anesthesia and Procedural Sedation

Ketamine was evaluated in the context of regulatory evidence as a dissociative anesthetic. The evidence includes both initial controlled clinical trials and decades of subsequent post-marketing surveillance and observational studies. Researchers primarily examined the drug's properties in achieving a trance-like state while monitoring outcomes related to systemic or functional imbalance, such as changes in heart rate and blood pressure.

The research describes patterns observed in the studies that are consistent with the compound’s properties, which were explored for use in necessary procedures. Studies consistently reported observations related to the preservation of protective airway reflexes. The majority of this foundational regulatory research applies only to the populations studied and primarily involves the standard racemic mixture of Ketamine.

Evidence for Use in Acute and Chronic Pain Management

Ketamine was evaluated in numerous Randomized Controlled Trials (RCTs) and systematic reviews exploring its application in managing outcomes related to physical discomfort, particularly severe acute pain after surgery or trauma. In the acute setting, research exploring short-term symptom changes data show patterns related to opioid consumption, where studies reported patients required lower amounts of additional opioid medication for pain relief.

For chronic pain syndromes, studies explored its use in conditions marked by functional limitations. However, findings were mixed and often described as heterogeneous due to significant variations in dosing and administration methods. The evidence quality varies across studies, and the follow-up durations were limited.

What Remains Uncertain and Areas for Future Research

While research provides context, not individual predictions, it highlights key areas where certainty remains low. The optimal protocols for chronic pain management are highly variable across studies, and the inconsistency of findings makes it difficult to draw broad conclusions. For treatment-resistant mood conditions, long-term effects of repeated use require further study regarding maintenance strategies. The results apply only to the populations studied, meaning the applicability of findings to patients who fall outside the specific enrollment criteria of major clinical trials remains uncertain.

Key Studies & References

1. Ketamine: National Library of Medicine (NIH) - StatPearls
2. Low-Dose Ketamine for Pain Management: An Overview of the Current Evidence

Common questions about Кетамин (FAQ)

Q: What is Ketamine used for?

A: Ketamine is officially approved by regulatory bodies, such as the U.S. FDA, as a general anesthetic. It is indicated for use as a sole anesthetic agent for certain diagnostic and surgical procedures that do not require skeletal muscle relaxation, for induction prior to administering other general anesthetics, and as a supplement to other anesthetic agents.

Q: What is the official legal status of Ketamine?

A: Ketamine is classified as a controlled substance in the United States and many other jurisdictions due to its potential for misuse. In the U.S., it is a Schedule III controlled substance under the Controlled Substances Act, meaning it has accepted medical uses but also a moderate to low potential for physical or psychological dependence.

Q: What are the potential serious side effects of Ketamine?

A: As noted in official prescribing information, Ketamine can potentially affect the cardiovascular system, often causing transient increases in heart rate and blood pressure. It may also cause respiratory issues, including respiratory depression, particularly if administered rapidly. Less commonly, serious psychological reactions, such as confusion, delirium, or hallucinations, have been observed. A healthcare professional monitors patients closely for these effects during administration.

Q: Can Ketamine be used for depression or pain management?

A: The FDA-approved indications for Ketamine are for use as a general anesthetic. Some specialized formulations, like esketamine (the S-enantiomer), have specific approvals for conditions like treatment-resistant depression. The use of Ketamine itself for depression or chronic pain outside of approved indications is considered an off-label use that requires careful medical supervision and is governed by specific clinical guidelines and regulations.

Q: How is Ketamine typically given?

A: Ketamine is a prescription-only medication administered by, or under the supervision of, licensed healthcare professionals. It can be administered through different routes, most commonly intravenously (IV) or intramuscularly (IM), depending on the specific medical need, the patient's condition, and the goals of the procedure.

Q: Is it safe to stop taking Ketamine if I’ve been using it for a while?

A: Ketamine is generally administered in a controlled medical setting for a specific procedure or course of treatment. If you have received Ketamine as part of a therapeutic plan, any change or cessation of treatment should only be decided by your treating physician. Stopping treatment without medical guidance is not recommended, and your healthcare provider is the best resource to discuss your treatment plan and any concerns about dependence or discontinuation.

The official storage requirements for Ketamine hydrochloride injection are defined by regulatory documents to maintain stability and integrity.

Storage Requirements

Condition	Requirement
Temperature	Store at 20 C to 25 C (68 F to 77 F), which aligns with USP Controlled Room Temperature. The product must not freeze [Source 1.6, 1.4].
Protection	Keep the product in the original container/outer carton to protect from light [Source 1.6].
Stability	Multi-dose vials must be discarded 28 days after initial use [Source 3.3]. Discard immediately if the solution is discolored or contains particulate matter [Source 1.7].
Child Safety	Keep out of the sight and reach of children and store locked up as a controlled substance [Source 2.1].

Disposal Instructions

Ketamine is for single use only, and any unused product must be discarded [Source 3.5]. As a controlled substance, disposal must follow all local, national, and international regulations for pharmaceutical waste, often requiring specific procedures such as DEA-authorized take-back programs [Source 2.4].